Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

138 results about "Staphylococcus aureus infections" patented technology

Only a couple are known to cause infections in humans. Staphylococcus aureus (S. aureus) is the most common cause of staph infections (see Staph Infection Causes). Probably the most well-known Staphylococcus bacteria are methicillin-resistant Staphylococcus aureus, or MRSA for short.

Monoclonal antibody for resisting staphylococcus aureus iron ion regulatory surface determinant B protein and application thereof

The invention discloses a monoclonal antibody for resisting staphylococcus aureus iron ion regulatory surface determinant B protein and application of the monoclonal antibody. Amino acid of a structural domain recognized by the monoclonal antibody is shown as SEQ ID NO.1. The monoclonal antibody is generated by culturing a host cell of an expression vector, the generated monoclonal antibody is secreted into supernate, and the supernate is secreted into the staphylococcus aureus iron ion regulatory surface determinant B protein to obtain the staphylococcus aureus iron ion regulatory surface determinant B. The staphylococcus aureus iron ion regulatory surface determinant B protein. Purifying through a chromatography technology; the obtained antibody can be used for treating septicopyemia caused by staphylococcus aureus / MRSA infection, and has important significance in preventing and treating staphylococcus aureus infection.
Owner:ARMY MEDICAL UNIV

Membrane vesicle preparation for eliminating intracellular staphylococcus aureus infection as well as preparation method and application of membrane vesicle preparation

The invention provides a membrane vesicle preparation for removing intracellular staphylococcus aureus infection and application of the membrane vesicle preparation, membrane vesicles of a staphylococcus aureus low-toxicity strain RN4220 are separated and purified, vancomycin is loaded by adopting an ultrasonic method, and the removal preparation is prepared, so that efficient delivery of vancomycin into macrophages is realized; the methicillin-resistant staphylococcus aureus in the macrophages can be effectively removed. By adopting the preparation provided by the invention, vancomycin can be effectively loaded into staphylococcus aureus membrane vesicles, the number of methicillin-resistant staphylococcus aureus infection in mouse peritoneal macrophages is remarkably reduced, and the preparation has relatively good biocompatibility and safety.
Owner:ARMY MEDICAL UNIV

Thiazolidinone compound and application of thiazolidinone compound in preparation of anti-staphylococcus aureus infection medicine

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.
Owner:SHENZHEN NANSHAN DISTRICT PEOPLES HOSPITAL

Antibody aiming at staphylococcus aureus enterotoxin B and application thereof

ActiveCN120988117AAntibacterial agentsGenetically modified cellsStaphylococcus aureus enterotoxin BStaphyloccocus aureus
The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.
Owner:CHONGQING YUANLUN BIOTECH

Preparation and biological activity application of single-layer Mo4VC4 nanosheet

The invention discloses an application of an Mxene-Mo4VC4 new member nano platform with light-enhanced peroxidase activity in treatment of methicillin-resistant staphylococcus aureus infection so as to promote healing of infected wounds, and belongs to the field of two-dimensional nano material catalyst antibacterial research. The single-layer Mo4VC4 nanosheet is synthesized on the basis of Mo4AlVC4-MXene through a hydrofluoric acid etching method. The Mo4VC4 nanosheet shows activity similar to peroxidase, and can locally catalyze low-concentration hydrogen peroxide and generate hydroxyl radicals toxic to bacteria, so that methicillin-resistant staphylococcus aureus is effectively killed, and a biological membrane is removed. In addition, high photo-thermal conversion efficiency and photo-thermal stability are shown under irradiation of near-infrared light with low concentration (50 mu g / mL). The similar peroxidase activity is obviously amplified by the temperature rise caused by the photothermal effect of the Mo4VC4 nanosheet. And finally, rapidly eliminating methicillin-resistant staphylococcus aureus in deep infection and accelerating abscess regression by adopting a satisfactory photo-thermal amplification peroxidase strategy.
Owner:WENZHOU MEDICAL UNIV

Application of fludarabine in treatment of methicillin-resistant staphylococcus aureus infection

The invention discloses application of fludarabine in treatment of methicillin-resistant staphylococcus aureus infection, and in an MRSA infected mouse model, it is verified that fludarabine can improve the survival rate of MRSA infected mice, reduce the MRSA bacterial count of lungs, livers, spleens and kidneys and relieve the injury degree of lungs, livers, spleens and kidneys caused by MRSA infection; pSMalpha3 is found to be an important virulence factor of MRSA, is closely related to high pathogenicity of MRSA, and can induce death of macrophages in a concentration-dependent manner, and fludarabine can significantly reduce cytotoxicity caused by PSMalpha3.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Application of compound 5928-0054 in preparation of anti-staphylococcus aureus hemolysin medicine

The invention discloses an application of a compound 5928-0054 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound 5928-0054 can neutralize the toxicity of staphylococcus aureus hemolysin, has a protection effect on mice infected by MRSA staphylococcus aureus USA300, and has the application of preparing the anti-staphylococcus aureus hemolysin medicine and the medicine for preventing or treating staphylococcus aureus infection. The new medicinal value of the compound 5928-0054 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound 5928-0054 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so that inflammatory injury is relieved.
Owner:SHANGHAI TOPSCIENCE CO LTD

Use of ferrous ions in the manufacture of a product for the treatment of a bacterial infection

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.
Owner:XIAN AIN LIFE TECHNOLOGY CO LTD

Vaccine for preventing and treating staphylococcus aureus mastitis and application thereof

The invention is applicable to the technical field of genetic engineering, and provides a vaccine for preventing and treating staphylococcus aureus mastitis and application of the vaccine. A recombinant bacillus subtilis construction method comprises the following steps: taking a DNA sequence as shown in SEQ ID NO.3 as a template, and performing PCR amplification to obtain a PCR product sequence; connecting the PCR product to a pHT43 vector, and converting the pHT43 vector into a competent cell DH5alpha, so as to obtain a recombinant plasmid pHT43-cCsa; the method comprises the following steps: transforming a recombinant plasmid pHT43-cCsa into a competent cell of bacillus subtilis WB800N, taking pHT43-F and pHT43-R as primers, and screening a positive transformant through a PCR (Polymerase Chain Reaction) technology; the recombinant bacillus subtilis for expressing the staphylococcus aureus Csa protein is constructed by utilizing a homologous recombination technology, so that pathological injury caused by staphylococcus aureus infection can be reduced, and staphylococcus aureus mastitis of dairy cattle can be prevented.
Owner:JILIN UNIVERSITY

Antibiotic-free hydrogel for nursing staphylococcus aureus infection as well as preparation method and application of antibiotic-free hydrogel

The invention discloses antibiotic-free hydrogel for nursing staphylococcus aureus infection as well as a preparation method and application of the antibiotic-free hydrogel. The hydrogel is prepared from metal ion compounds such as zinc ions, copper ions and iron ion compounds, a natural high polymer material and an antioxidant as raw materials, and has the advantages of efficient antibacterial property, high safety, long-acting slow release and the like. An in-vitro antibacterial experiment shows that the sterilizing rate of the metal ion compound on staphylococcus aureus can reach 90%-99.9%; animal experiments prove that the hydrogel can effectively relieve inflammatory reaction of infected parts, and skin irritation experiments show that the product is free of irritation and anaphylactic reaction. The invention provides a safe and effective nonreactive solution for nursing of staphylococcus aureus infection.
Owner:SHAANXI UNIV OF SCI & TECH

Single-layer wmos2 nanosheet and preparation method and application thereof

The application belongs to the field of antibacterial two-dimensional nanomaterial Mxene catalysts, and particularly relates to a monolayer W@MoS2 nanosheet as well as a preparation method and application thereof. The method comprises the following steps: 1) dissolving water-soluble molybdate and water-soluble tungstate in water to obtain a mixed solution; 2) adding a sulfur source and an organic solvent to the mixed solution, and then performing reaction after mixing, and drying to obtain a powder. The monolayer W@MoS2 nanosheet has a unique two-dimensional planar structure, a large specific surface area, and good optical and electronic properties, and has high light-heat absorption in the near-infrared two region, i.e., the light-heat conversion efficiency is improved. Meanwhile, the peroxidase-like activity of the monolayer W@MoS2 nanosheet material realizes efficient light-heat amplification, can treat methicillin-resistant Staphylococcus aureus infection, and avoids heat therapy damage to normal tissues.
Owner:CHINA GENE PHARMVALLEY

Aminoguanidine tetralone derivative as well as preparation method and application thereof

The invention relates to the technical field of medicine synthesis, and particularly discloses an aminoguanidine tetralone derivative and a structural general formula of the aminoguanidine tetralone derivative. The invention also discloses a preparation method and application of the derivative. The aminoguanidine tetralone derivative has a good inhibiting and killing effect on staphylococcus aureus and can be used for preventing and treating diseases caused by staphylococcus aureus infection.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS

Small molecule compound of PPP2CB phosphatase target and application thereof

The invention relates to a PPP2CB phosphatase target small molecule compound and application thereof, and belongs to the field of biological medicine. The invention provides a small molecule compound C16H16N4O, which is specifically combined with a PPP2CB catalytic subunit, and by enhancing the activity of PPP2CB phosphatase, the serine / threonine phosphorylation level of ERK, MAPK, JAK and other kinases in macrophages is remarkably reduced, and the activation of NF-kappa B, JAK-STAT and MAPK-ERK inflammation signal pathways is blocked. The compound is suitable for treating inflammatory storm caused by SARS-CoV-2, influenza virus and staphylococcus aureus infection. In an SARS-CoV-2 infection model, the survival rate of the mice is increased from 0 to 50%; the lung pathological injury is relieved after influenza virus infection. Sepsis caused by staphylococcus aureus USA300 is effectively inhibited, and the death rate is reduced. The clinical transformation potential is realized.
Owner:ARMY MEDICAL UNIV

Cell wall degrading enzymes with antibacterial activity

The present invention relates to a series of cell wall degrading enzymes with antibacterial activity for effectively controlling Staphylococcus aureus, and the cell wall degrading enzymes with antibacterial activity of the present invention are a series of lyases with new amino acid sequences. The cell wall degrading enzymes with antibacterial activity of the present invention can be used as agents capable of effectively inhibiting Staphylococcus aureus, and can be applied to the disinfection of Staphylococcus aureus in the environment and the treatment of diseases caused by Staphylococcus aureus infection, etc.
Owner:BIOCREATECH (SHENZHEN) BIOTECHNOLOGY CO LTD

Single-layer W-coated MoS2 nanosheet as well as preparation method and application thereof

The invention belongs to the field of antibacterial two-dimensional nano material Mxene catalysts, and particularly relates to a single-layer W-coated MoS2 nanosheet as well as a preparation method and application thereof. The method comprises the following steps: 1) dissolving water-soluble molybdate and water-soluble tungstate in water, and uniformly mixing to obtain a mixed solution; and 2) adding a sulfur source and an organic solvent into the mixed solution, mixing, reacting, and drying to obtain powder. The single-layer W-coated MoS2 nanosheet has a unique two-dimensional plane structure, is large in specific surface area, shows good optical and electronic properties, and is high in photo-thermal absorption in a near-infrared second region, that is, the photo-thermal conversion efficiency is improved, meanwhile, efficient photo-thermal amplification is achieved through peroxidase-like activity of the single-layer W-coated MoS2 nanosheet material, and the photo-thermal conversion efficiency is improved. And the anti-methicillin-resistant staphylococcus aureus infection treatment can be carried out, and the thermal therapy injury to normal tissues is avoided.
Owner:CHINA GENE PHARMVALLEY

An mRNA encoding anti-Staphylococcus aureus enterotoxin B antibody and its application

ActiveCN119320780BAntibacterial agentsImmunoglobulins against bacteriaStaphylococcus aureus enterotoxin BBacterial enterotoxins
The present invention discloses an mRNA encoding an anti-Staphylococcus aureus enterotoxin B antibody and an application thereof. The mRNA comprises an mRNA encoding a light chain of the anti-Staphylococcus aureus enterotoxin B antibody and an mRNA encoding a heavy chain of the anti-Staphylococcus aureus enterotoxin B antibody, wherein the optimized base sequences of the variable regions CDR1, CDR2 and CDR3 of the heavy chain are shown as SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, respectively; and the optimized base sequences of the variable regions CDR1, CDR2 and CDR3 of the light chain are shown as SEQ ID NO.7, SEQ ID NO.8 and SEQ ID NO.9. The antibody can be used to neutralize SEB toxin and simultaneously prevent and treat Staphylococcus aureus infection.
Owner:ARMY MEDICAL UNIV

Synthesis of four quaternary ammonium salt derivatives and their application in treating Staphylococcus aureus infection

The present invention discloses four quaternary ammonium salt derivatives, their synthesis methods, and applications. One quaternary ammonium salt derivative of the present invention has the chemical name (E)-N,N,N-trimethyl-1-(4-(phenyldiazenyl)phenyl)methylammonium bromide (Compound 1e). Compound 1e, synthesized using aniline as a starting material, exhibits excellent antibacterial activity against Staphylococcus aureus at 500 μg / mL.
Owner:NINGBO INST OF NORTHWESTERN POLYTECHNICAL UNIV

Antibodies against staphylococcus aureus isdb and uses thereof

The application discloses an antibody against Staphylococcus aureus IsdB and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are respectively shown as SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11. In addition, the application further discloses a product for detecting Staphylococcus aureus IsdB and application of the antibody in preparation of a diagnosis, prevention and / or treatment of diseases related to Staphylococcus aureus infection. The application provides a new idea for detection of Staphylococcus aureus IsdB and treatment of related diseases, and has a wide application prospect.
Owner:CHONGQING YUANLUN BIOTECH

Application of SX-682 in preparation of drugs for resisting staphylococcus aureus infection

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.
Owner:SHENZHEN NANSHAN DISTRICT PEOPLES HOSPITAL

Bacillus cereus aminomethyltransferase antibacterial peptide BA14 and application thereof

The invention discloses a bacillus cereus aminomethyltransferase antibacterial peptide BA14, the amino acid sequence of the bacillus cereus aminomethyltransferase antibacterial peptide BA14 is HKKEMVLAWLQNQK, and the molecular weight of the antibacterial peptide is 1753.092 Daltons. The antibacterial peptide disclosed by the invention has an obvious inhibiting effect on staphylococcus aureus and can be used for preparing a medicine or a feed additive for preventing or inhibiting staphylococcus aureus infection. Researches show that the antibacterial peptide BA14 and vitamin D3 are combined for use, so that the growth of staphylococcus aureus can be killed or strongly inhibited.
Owner:GUANGZHOU TAIWEI FEED CO LTD

Preparation and biological activity application of hexagonal copper sulfide

The invention discloses an application of a hexagonal copper sulfide nano-platform with photo-thermal enhanced peroxidase activity in treatment of methicillin-resistant staphylococcus aureus infection so as to promote healing of infected wounds. An improved one-pot method is adopted to synthesize a hexagonal copper sulfide nano-sheet. Due to the fact that the hexagonal copper sulfide nanosheet shows good photothermal conversion efficiency and photothermal stability in a second near-infrared window and further shows excellent peroxidase-like activity, temperature rise caused by the photothermal effect of the hexagonal copper sulfide nanosheet remarkably amplifies the peroxidase-like activity of the hexagonal copper sulfide nanosheet. The hexagonal copper sulfide nanosheet plays a good biological catalytic antibacterial role in vitro, under photo-thermal irradiation, abscess fading and healing of in-vivo methicillin-resistant staphylococcus aureus infected wounds are promoted, and toxicity can be ignored. The copper sulfide nanosheet provides a feasible strategy for effectively treating a deep methicillin-resistant staphylococcus aureus infected wound by utilizing a synergistic treatment platform.
Owner:WENZHOU MEDICAL UNIV

Application of idebenone in preparation of antibacterial product

The invention discloses an application of idebenone in preparation of an antibacterial product. According to the invention, the in-vitro antibacterial activity and antibacterial spectrum of idebenone on clinical common strains are researched, and the research result shows that idebenone has an inhibiting effect on the growth of staphylococcus aureus. When the concentration of idebenone is within the range of 32-128 mu g / mL, growth of drug-resistant and sensitive staphylococcus aureus can be remarkably inhibited. Therefore, idebenone can be used for treating staphylococcus aureus infection and can be used for preparing antibacterial products.
Owner:NO 1 THE PEOPLES HOSPITAL HUAIAN CITY

Composite drug-loaded nanoparticle based on acylated polysaccharide and berberine as well as preparation method and application of composite drug-loaded nanoparticle

The invention relates to the technical field of nano-medicine carriers, in particular to composite drug-loaded nanoparticles based on acylated polysaccharide and berberine as well as a preparation method and application of the composite drug-loaded nanoparticles. The preparation method comprises the following steps: carrying out acylation modification on natural polysaccharide by using a basic catalyst and acid anhydride to obtain acylated natural polysaccharide; wherein the acylation modification mode comprises acetylation modification or propionylation modification; in an organic solvent, the berberine and the acylated natural polysaccharide are subjected to encapsulation treatment, and the composite drug-loaded nanoparticles based on the acylated polysaccharide and the berberine are obtained. According to the preparation method, the natural polysaccharide is subjected to acylation modification, the hydrophobicity of the natural polysaccharide is adjusted, and the encapsulation efficiency of berberine is remarkably improved. On one hand, the composite drug-loaded nanoparticles can significantly improve the bioavailability of berberine and prolong the in-vivo action time of berberine, and on the other hand, the composite drug-loaded nanoparticles can promote the repair and healing of wounds infected by staphylococcus aureus and reduce the drug resistance of staphylococcus aureus.
Owner:CHENGDU UNIV

An antibacterial peptide derived from the skin of bullfrog and application thereof

The application discloses an antibacterial peptide derived from the skin of bullfrog and application thereof, and the amino acid sequence of the antibacterial peptide is GSVGPVGPR (as shown in SEQ ID NO:1), and the molecular weight is 824.4504 g / mol. The antibacterial peptide has obvious inhibiting effect on Staphylococcus aureus, and can be used for preparing a medicine for preventing or inhibiting Staphylococcus aureus infection. Meanwhile, the antibacterial peptide and vitamin A have a significant synergistic bactericidal effect on Staphylococcus aureus. The antibacterial peptide and vitamin A can significantly reduce the use concentration of single component, improve the antibacterial efficiency, overcome the bacterial drug resistance problem, and can be used for preparing antibacterial medicines, skin external preparation, medical dressings, feed additives and food preservatives.
Owner:GUANGZHOU TAIWEI FEED CO LTD

An antibody-antibiotic conjugate and uses thereof

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.
Owner:EAST CHINA UNIV OF SCI & TECH +1

A Bacillus cereus aminomethyltransferase antimicrobial peptide BA14 and its application

The present invention discloses a Bacillus cereus aminomethyltransferase antimicrobial peptide BA14, whose amino acid sequence is HKKEMVLAWLQNQK, and the molecular weight of the antimicrobial peptide is 1753.092 Daltons. The antimicrobial peptide of the present invention has a significant inhibitory effect on Staphylococcus aureus, and can be used as a medicine or feed additive for preparing a drug for preventing or inhibiting Staphylococcus aureus infection. Studies have shown that the antimicrobial peptide BA14 of the present invention combined with vitamin D3 can kill or strongly inhibit the growth of Staphylococcus aureus.
Owner:GUANGZHOU TAIWEI FEED CO LTD

A fully human SEB monoclonal antibody against Staphylococcus aureus enterotoxin B and its application

ActiveCN116178534BAntibacterial agentsGenetically modified cellsStaphylococcus aureus enterotoxin BStaphyloccocus aureus
The present invention discloses a fully human SEB monoclonal antibody against Staphylococcus aureus enterotoxin B and its applications. The amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the heavy chain of the antibody are shown as SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.7 respectively; the amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the light chain are shown as SEQ ID NO.9, SEQ ID NO.10, and SEQ ID NO.11 respectively; the antibody can specifically bind to Staphylococcus aureus enterotoxin B and can be used for the treatment, prevention, or diagnosis of Staphylococcus aureus infections and toxic shock syndrome caused by enterotoxin B, which will become an important direction in the research field of "non-antibiotic" treatment of drug-resistant Staphylococcus aureus infections and control of the development of drug resistance.
Owner:ARMY MEDICAL UNIV

Preparation method of phenol derivative capable of effectively inhibiting staphylococcus aureus

The invention discloses a preparation method of a phenol derivative capable of effectively inhibiting staphylococcus aureus, and belongs to the technical field of synthesis and application of medical intermediates. The preparation method comprises the following steps: under the conditions of protective atmosphere and illumination, carrying out an addition reaction on 4-benzal-2, 6-di-tert-butylcyclohexane-2, 5-diene-1-ketone and cyclohexane under the action of 4-nitrophthalonitrile, so as to obtain the 2, 6-di-tert-butyl-4-(cyclohexyl (phenyl) methyl) phenol. The preparation method has the advantages of simplicity in operation, mild reaction conditions, low cost of used reagents, high yield and the like, is favorable for realizing large-scale production, provides a key intermediate support for developing low-cost and high-activity anti-staphylococcus aureus drugs, and has important significance in relieving clinical drug-resistant staphylococcus aureus infection treatment dilemma.
Owner:DONGGUAN EASTERN CENT HOSPITAL

A garlic-derived exosome granule wound dressing and its preparation method and application

ActiveCN118079072BRealize visual detectionQuick GlueCell dissociation methodsPlant cellsBiotechnologyInfected cell
The invention discloses a garlic-derived exosome granule wound dressing and a preparation method and application thereof. The garlic-derived exosome granule wound dressing (Gel Van@GELNs) comprises garlic-derived exosome granules (Van@GELNs) loaded with antibiotics, hydrogel, 2,2-azino-bis(3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt and horseradish peroxidase. The 2,2-azino-bis(3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt in the dressing and H2O2 overexpressed at the wound infection site are green under the catalysis of horseradish peroxidase to realize the visual detection of Staphylococcus aureus infection. Meanwhile, Gel Van@GELNs continuously releases Van@GELNs at the wound infection site, and Van@GELNs can be delivered into infected cells through cell membranes and release Van, thereby realizing the treatment of intracellular Staphylococcus aureus infection and enhancing its effect in treating refractory infectious-related diseases.
Owner:SOUTHEAST UNIV

Use of an antimicrobial peptide in preparing a drug for resisting Staphylococcus aureus infection

The present invention provides a use of an antimicrobial peptide in the preparation of a drug for resisting Staphylococcus aureus infection. In a pneumonia mouse model infected with Staphylococcus aureus, the therapeutic effect of GHb3K and GHbK4R is better than that of vancomycin, the inflammatory response can be significantly reduced, and the in vivo toxicity is lower than that of vancomycin. GHb3K and GHbR can significantly promote the healing of chronic infectious wounds of methicillin-resistant Staphylococcus aureus (MRSA), and the therapeutic effect is better than that of mupirocin ointment. The antimicrobial peptide provided by the present invention has the potential to be developed into a drug for treating pneumonia infected with Staphylococcus aureus and a drug for treating chronic wounds infected with MRSA.
Owner:HAINAN UNIV